Amirrtha Srikanthan1, Ben Tran1, Michel Beausoleil1, Michael A S Jewett1, Robert J Hamilton1, Jeremy F G Sturgeon1, Martin O'Malley1, Lynn Anson-Cartwright1, Peter W M Chung1, Padraig R Warde1, Eric Winquist1, Malcolm J Moore1, Eitan Amir1, Philippe L Bedard2. 1. Amirrtha Srikanthan, Ben Tran, Michael A.S. Jewett, Robert J. Hamilton, Lynn Anson-Cartwright, Peter W.M. Chung, Padraig R. Warde, Martin O'Malley, Malcolm J. Moore, Eitan Amir, and Philippe L. Bedard, Princess Margaret Cancer Centre, University of Toronto, Toronto; Michel Beausoleil and Eric Winquist, Western University and London Health Sciences Centre, London, Ontario; Jeremy F.G. Sturgeon, McGill University, Montreal, Quebec, Canada; and Ben Tran, Royal Melbourne Hospital, Melbourne, Victoria, Australia. 2. Amirrtha Srikanthan, Ben Tran, Michael A.S. Jewett, Robert J. Hamilton, Lynn Anson-Cartwright, Peter W.M. Chung, Padraig R. Warde, Martin O'Malley, Malcolm J. Moore, Eitan Amir, and Philippe L. Bedard, Princess Margaret Cancer Centre, University of Toronto, Toronto; Michel Beausoleil and Eric Winquist, Western University and London Health Sciences Centre, London, Ontario; Jeremy F.G. Sturgeon, McGill University, Montreal, Quebec, Canada; and Ben Tran, Royal Melbourne Hospital, Melbourne, Victoria, Australia. Philippe.Bedard@uhn.ca.
Abstract
PURPOSE: Cisplatin-based chemotherapy, a mainstay of treatment for disseminated germ cell tumors (GCTs), is associated with venous thromboembolism (VTE). Many patients with disseminated GCTs have large retroperitoneal lymph node (RPLN) metastases that may cause venous stasis and increase the risk of VTE development. We hypothesized that there was an association between large RPLN and chemotherapy-associated VTE risk. PATIENTS AND METHODS: The training cohort was composed of patients with disseminated GCT receiving first-line chemotherapy at Princess Margaret Cancer Centre between January 2000 and December 2010. Large RPLN was defined as more than 5 cm in maximal axial diameter. The predictive and discriminatory accuracies of a model using large RPLN in predicting VTE were compared with high-risk Khorana score (≥ 3) using logistic regression and area under receiver operator characteristic curves (AUROCs). The model was externally validated in a cohort of patients treated at the London Health Sciences Centre. RESULTS: The training cohort comprised 216 patients, 21 (10%) of whom developed VTE during chemotherapy. VTE was associated with large RPLN (odds ratio [OR], 5.26; P = .001), high-risk Khorana score (OR, 11.8; P < .001), intermediate-/poor-risk disease (OR, 3.76; P = .005), and hospitalization during chemotherapy (OR, 4.24; P = .002). Large RPLN showed higher discriminatory accuracy than high-risk Khorana score (AUROC, 0.71 v 0.67, respectively). Superior discriminatory accuracy of large RPLN over high-risk Khorana score was validated in the London cohort (AUROC, 0.61 v 0.57, respectively). CONCLUSION: Large RPLN is associated with VTE in patients with disseminated GCT and provides higher discriminatory accuracy than high-risk Khorana score. Results should be validated in larger, prospective studies. Prophylactic anticoagulation may be considered in high-risk patients.
PURPOSE:Cisplatin-based chemotherapy, a mainstay of treatment for disseminated germ cell tumors (GCTs), is associated with venous thromboembolism (VTE). Many patients with disseminated GCTs have large retroperitoneal lymph node (RPLN) metastases that may cause venous stasis and increase the risk of VTE development. We hypothesized that there was an association between large RPLN and chemotherapy-associated VTE risk. PATIENTS AND METHODS: The training cohort was composed of patients with disseminated GCT receiving first-line chemotherapy at Princess Margaret Cancer Centre between January 2000 and December 2010. Large RPLN was defined as more than 5 cm in maximal axial diameter. The predictive and discriminatory accuracies of a model using large RPLN in predicting VTE were compared with high-risk Khorana score (≥ 3) using logistic regression and area under receiver operator characteristic curves (AUROCs). The model was externally validated in a cohort of patients treated at the London Health Sciences Centre. RESULTS: The training cohort comprised 216 patients, 21 (10%) of whom developed VTE during chemotherapy. VTE was associated with large RPLN (odds ratio [OR], 5.26; P = .001), high-risk Khorana score (OR, 11.8; P < .001), intermediate-/poor-risk disease (OR, 3.76; P = .005), and hospitalization during chemotherapy (OR, 4.24; P = .002). Large RPLN showed higher discriminatory accuracy than high-risk Khorana score (AUROC, 0.71 v 0.67, respectively). Superior discriminatory accuracy of large RPLN over high-risk Khorana score was validated in the London cohort (AUROC, 0.61 v 0.57, respectively). CONCLUSION: Large RPLN is associated with VTE in patients with disseminated GCT and provides higher discriminatory accuracy than high-risk Khorana score. Results should be validated in larger, prospective studies. Prophylactic anticoagulation may be considered in high-risk patients.
Authors: Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu Journal: Curr Opin Oncol Date: 2017-05 Impact factor: 3.645
Authors: Chunkit Fung; Sophie D Fossa; Michael T Milano; Deepak M Sahasrabudhe; Derick R Peterson; Lois B Travis Journal: J Clin Oncol Date: 2015-08-03 Impact factor: 44.544
Authors: Samuel A Funt; Deaglan J McHugh; Stephanie Tsai; Andrea Knezevic; Devon O'Donnell; Sujata Patil; Deborah Silber; Maria Bromberg; Maryann Carousso; Victor E Reuter; Brett S Carver; Joel Sheinfeld; Robert J Motzer; Dean F Bajorin; George J Bosl; Darren R Feldman Journal: Oncologist Date: 2021-03-12
Authors: Nick van Es; Marcello Di Nisio; Gabriela Cesarman; Ankie Kleinjan; Hans-Martin Otten; Isabelle Mahé; Ineke T Wilts; Desirée C Twint; Ettore Porreca; Oscar Arrieta; Alain Stépanian; Kirsten Smit; Michele De Tursi; Suzanne M Bleker; Patrick M Bossuyt; Rienk Nieuwland; Pieter W Kamphuisen; Harry R Büller Journal: Haematologica Date: 2017-05-26 Impact factor: 9.941
Authors: Fiorella Guadagni; Silvia Riondino; Vincenzo Formica; Girolamo Del Monte; Anna Maria Morelli; Jessica Lucchetti; Antonella Spila; Roberta D'Alessandro; David Della-Morte; Patrizia Ferroni; Mario Roselli Journal: World J Gastroenterol Date: 2017-07-28 Impact factor: 5.742
Authors: Angelika Bezan; Florian Posch; Ferdinand Ploner; Thomas Bauernhofer; Martin Pichler; Joanna Szkandera; Georg C Hutterer; Karl Pummer; Thomas Gary; Hellmut Samonigg; Joerg Beyer; Thomas Winder; Thomas Hermanns; Christian D Fankhauser; Armin Gerger; Michael Stotz Journal: PLoS One Date: 2017-04-21 Impact factor: 3.240
Authors: Andrés J Muñoz Martín; Israel Ortega; Carme Font; Vanesa Pachón; Victoria Castellón; Virginia Martínez-Marín; Mercedes Salgado; Eva Martínez; Julia Calzas; Ana Rupérez; Juan C Souto; Miguel Martín; Eduardo Salas; Jose M Soria Journal: Br J Cancer Date: 2018-03-28 Impact factor: 7.640